145 related articles for article (PubMed ID: 35137340)
41. A risk-adjusted approach to comparing the return on investment in health care programs.
Sendi P; Al MJ; Zimmermann H
Int J Health Care Finance Econ; 2004 Sep; 4(3):199-210. PubMed ID: 15277778
[TBL] [Abstract][Full Text] [Related]
42. Representing uncertainty: the role of cost-effectiveness acceptability curves.
Fenwick E; Claxton K; Sculpher M
Health Econ; 2001 Dec; 10(8):779-87. PubMed ID: 11747057
[TBL] [Abstract][Full Text] [Related]
43. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
44. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane.
Briggs A; Fenn P
Health Econ; 1998 Dec; 7(8):723-40. PubMed ID: 9890333
[TBL] [Abstract][Full Text] [Related]
45. The cost-effectiveness of screening for oral cancer in primary care.
Speight PM; Palmer S; Moles DR; Downer MC; Smith DH; Henriksson M; Augustovski F
Health Technol Assess; 2006 Apr; 10(14):1-144, iii-iv. PubMed ID: 16707071
[TBL] [Abstract][Full Text] [Related]
46. Improving Maternal Care through a State-Wide Health Insurance Program: A Cost and Cost-Effectiveness Study in Rural Nigeria.
Gomez GB; Foster N; Brals D; Nelissen HE; Bolarinwa OA; Hendriks ME; Boers AC; van Eck D; Rosendaal N; Adenusi P; Agbede K; Akande TM; Boele van Hensbroek M; Wit FW; Hankins CA; Schultsz C
PLoS One; 2015; 10(9):e0139048. PubMed ID: 26413788
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness league tables: valuable guidance for decision makers?
Mauskopf J; Rutten F; Schonfeld W
Pharmacoeconomics; 2003; 21(14):991-1000. PubMed ID: 13129413
[TBL] [Abstract][Full Text] [Related]
48. Uncertainty and the decision maker: assessing and managing the risk of undesirable outcomes.
Gafni A; Walter S; Birch S
Health Econ; 2013 Nov; 22(11):1287-94. PubMed ID: 23280702
[TBL] [Abstract][Full Text] [Related]
49. Opportunity costs and uncertainty in the economic evaluation of health care interventions.
Sendi P; Gafni A; Birch S
Health Econ; 2002 Jan; 11(1):23-31. PubMed ID: 11788979
[TBL] [Abstract][Full Text] [Related]
50. The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment.
Grimm SE; Strong M; Brennan A; Wailoo AJ
Pharmacoeconomics; 2017 Dec; 35(12):1287-1296. PubMed ID: 28849538
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of a Stratified National Breast Screening Program in the United Kingdom: An Early Model-Based Cost-Effectiveness Analysis.
Gray E; Donten A; Karssemeijer N; van Gils C; Evans DG; Astley S; Payne K
Value Health; 2017 Sep; 20(8):1100-1109. PubMed ID: 28964442
[TBL] [Abstract][Full Text] [Related]
52. Decision making for group risk reduction: dealing with epistemic uncertainty.
Bedford T
Risk Anal; 2013 Oct; 33(10):1884-98. PubMed ID: 23557192
[TBL] [Abstract][Full Text] [Related]
53. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
54. Routine real-time cost-effectiveness monitoring of a web-based depression intervention: a risk-sharing proposal.
Naveršnik K; Mrhar A
J Med Internet Res; 2014 Feb; 16(2):e67. PubMed ID: 24583773
[TBL] [Abstract][Full Text] [Related]
55. Evolution of a cost-utility model of donepezil for Alzheimer's disease.
Peters JL; Anderson R; Hoyle M; Hyde C
Int J Technol Assess Health Care; 2013 Apr; 29(2):147-54. PubMed ID: 23514698
[TBL] [Abstract][Full Text] [Related]
56. Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach.
Lakdawalla DN; Phelps CE
Value Health; 2021 Feb; 24(2):244-249. PubMed ID: 33518031
[TBL] [Abstract][Full Text] [Related]
57. Development of an economic model to assess the cost effectiveness of asthma management strategies.
Price MJ; Briggs AH
Pharmacoeconomics; 2002; 20(3):183-94. PubMed ID: 11929348
[TBL] [Abstract][Full Text] [Related]
58. Portfolio theory and cost-effectiveness analysis: a further discussion.
Sendi P; Al MJ; Rutten FF
Value Health; 2004; 7(5):595-601. PubMed ID: 15367254
[TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
Pinkerton SD; Holtgrave DR; Pinkerton HJ
Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
[TBL] [Abstract][Full Text] [Related]
60. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part II--results.
Blute M; Ackerman SJ; Rein AL; Beusterien K; Sullivan EM; Tanio CP; Strauss MJ; Manyak MJ
Urology; 2000 Dec; 56(6):981-7. PubMed ID: 11113744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
